This opportunity funds the creation of a research network to study rapid-acting psychotropic interventional drugs like ketamine, esketamine, and psilocybin. It focuses on generating rigorous real-world evidence regarding their clinical effectiveness, safety, durability, and implementation in diverse healthcare settings to inform safe and effective integration into clinical care.
Eligible applicants include a wide range of government entities, educational institutions, nonprofits, for-profit organizations, tribal governments, and regional organizations. Specific eligibility includes state, county, city governments, tribal organizations, nonprofits with or without 501(c)(3) s
